Drug Profile
Research programme: seliciclib derivatives - Cyclacel Pharmaceuticals
Latest Information Update: 26 Mar 2016
Price :
$50
*
At a glance
- Originator Cyclacel Pharmaceuticals
- Class Purines
- Mechanism of Action Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 11 May 2009 Preclinical trials in Cancer in United Kingdom (PO)